img

Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
Antidiabetic Glucagon-like Peptide 1 Agonists report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Antidiabetic Glucagon-like Peptide 1 Agonists market is projected to reach US$ 7350.9 million in 2029, increasing from US$ 5387 million in 2022, with the CAGR of 4.3% during the period of 2024 to 2029. Demand from Hospital and Pharmacy are the major drivers for the industry.
The Glucagon-like peptide 1 (GLP-1) market is driven by the increasing prevalence of diabetes and the growing demand for effective and innovative diabetes treatments. GLP-1 is a hormone that plays a crucial role in regulating blood sugar levels and is used in the treatment of type 2 diabetes. The rise in the number of diabetic patients and the need for better glycemic control contribute to market growth as GLP-1-based therapies offer significant benefits, including glucose-lowering effects and weight management. Moreover, advancements in GLP-1 analog formulations, such as long-acting and once-weekly options, have improved patient compliance and treatment outcomes. However, the market also faces challenges, including the cost of GLP-1 treatments and the need for further research to optimize dosing and combination therapies. Additionally, addressing the barriers to GLP-1 adoption, such as injection-related fears, can pose obstacles for broader market penetration. To succeed, companies must focus on research and development to offer innovative and cost-effective GLP-1 therapies, collaborate with healthcare providers to optimize treatment regimens, and address the challenges to meet the increasing demand for effective and well-tolerated diabetes treatments based on GLP-1.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Antidiabetic Glucagon-like Peptide 1 Agonists market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Abbott Laboratories
Segment by Type
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide

Segment by Application


Hospital
Pharmacy

Segment by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Antidiabetic Glucagon-like Peptide 1 Agonists market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Antidiabetic Glucagon-like Peptide 1 Agonists, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Antidiabetic Glucagon-like Peptide 1 Agonists industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Antidiabetic Glucagon-like Peptide 1 Agonists in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Antidiabetic Glucagon-like Peptide 1 Agonists introduction, etc. Antidiabetic Glucagon-like Peptide 1 Agonists Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Antidiabetic Glucagon-like Peptide 1 Agonists market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Antidiabetic Glucagon-like Peptide 1 Agonists Market Overview
1.1 Antidiabetic Glucagon-like Peptide 1 Agonists Product Overview
1.2 Antidiabetic Glucagon-like Peptide 1 Agonists Market Segment by Type
1.2.1 Exenatied
1.2.2 Liraglutide
1.2.3 Lixisenatide
1.2.4 Albiglutide
1.2.5 Dulaglutide
1.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Type
1.3.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Size Overview by Type (2018-2029)
1.3.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Historic Market Size Review by Type (2018-2024)
1.3.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Breakdown by Type (2018-2024)
1.4.2 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Breakdown by Type (2018-2024)
2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Competition by Company
2.1 Global Top Players by Antidiabetic Glucagon-like Peptide 1 Agonists Sales (2018-2024)
2.2 Global Top Players by Antidiabetic Glucagon-like Peptide 1 Agonists Revenue (2018-2024)
2.3 Global Top Players by Antidiabetic Glucagon-like Peptide 1 Agonists Price (2018-2024)
2.4 Global Top Manufacturers Antidiabetic Glucagon-like Peptide 1 Agonists Manufacturing Base Distribution, Sales Area, Product Type
2.5 Antidiabetic Glucagon-like Peptide 1 Agonists Market Competitive Situation and Trends
2.5.1 Antidiabetic Glucagon-like Peptide 1 Agonists Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Antidiabetic Glucagon-like Peptide 1 Agonists Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Antidiabetic Glucagon-like Peptide 1 Agonists as of 2022)
2.7 Date of Key Manufacturers Enter into Antidiabetic Glucagon-like Peptide 1 Agonists Market
2.8 Key Manufacturers Antidiabetic Glucagon-like Peptide 1 Agonists Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Antidiabetic Glucagon-like Peptide 1 Agonists Status and Outlook by Region
3.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Historic Market Size by Region
3.2.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Volume by Region (2018-2024)
3.2.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Value by Region (2018-2024)
3.2.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Forecasted Market Size by Region
3.3.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Volume by Region (2024-2029)
3.3.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Value by Region (2024-2029)
3.3.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Antidiabetic Glucagon-like Peptide 1 Agonists by Application
4.1 Antidiabetic Glucagon-like Peptide 1 Agonists Market Segment by Application
4.1.1 Hospital
4.1.2 Pharmacy
4.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Application
4.2.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Size Overview by Application (2018-2029)
4.2.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Historic Market Size Review by Application (2018-2024)
4.2.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Breakdown by Application (2018-2024)
4.3.2 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Breakdown by Application (2018-2024)
5 North America Antidiabetic Glucagon-like Peptide 1 Agonists by Country
5.1 North America Antidiabetic Glucagon-like Peptide 1 Agonists Historic Market Size by Country
5.1.1 North America Antidiabetic Glucagon-like Peptide 1 Agonists Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Volume by Country (2018-2024)
5.1.3 North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Value by Country (2018-2024)
5.2 North America Antidiabetic Glucagon-like Peptide 1 Agonists Forecasted Market Size by Country
5.2.1 North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Volume by Country (2024-2029)
5.2.2 North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Value by Country (2024-2029)
6 Europe Antidiabetic Glucagon-like Peptide 1 Agonists by Country
6.1 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Historic Market Size by Country
6.1.1 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Volume by Country (2018-2024)
6.1.3 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Value by Country (2018-2024)
6.2 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Forecasted Market Size by Country
6.2.1 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Volume by Country (2024-2029)
6.2.2 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Value by Country (2024-2029)
7 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists by Region
7.1 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Historic Market Size by Region
7.1.1 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Forecasted Market Size by Region
7.2.1 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Value by Region (2024-2029)
8 Latin America Antidiabetic Glucagon-like Peptide 1 Agonists by Country
8.1 Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Historic Market Size by Country
8.1.1 Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Volume by Country (2018-2024)
8.1.3 Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Value by Country (2018-2024)
8.2 Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Forecasted Market Size by Country
8.2.1 Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Volume by Country (2024-2029)
8.2.2 Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Value by Country (2024-2029)
9 Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists by Country
9.1 Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Historic Market Size by Country
9.1.1 Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Forecasted Market Size by Country
9.2.1 Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Novo Nordisk
10.1.1 Novo Nordisk Company Information
10.1.2 Novo Nordisk Introduction and Business Overview
10.1.3 Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Products Offered
10.1.5 Novo Nordisk Recent Development
10.2 AstraZeneca
10.2.1 AstraZeneca Company Information
10.2.2 AstraZeneca Introduction and Business Overview
10.2.3 AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Sales, Revenue and Gross Margin (2018-2024)
10.2.4 AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Products Offered
10.2.5 AstraZeneca Recent Development
10.3 Eli Lily
10.3.1 Eli Lily Company Information
10.3.2 Eli Lily Introduction and Business Overview
10.3.3 Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Products Offered
10.3.5 Eli Lily Recent Development
10.4 GSK
10.4.1 GSK Company Information
10.4.2 GSK Introduction and Business Overview
10.4.3 GSK Antidiabetic Glucagon-like Peptide 1 Agonists Sales, Revenue and Gross Margin (2018-2024)
10.4.4 GSK Antidiabetic Glucagon-like Peptide 1 Agonists Products Offered
10.4.5 GSK Recent Development
10.5 Sanofi
10.5.1 Sanofi Company Information
10.5.2 Sanofi Introduction and Business Overview
10.5.3 Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Products Offered
10.5.5 Sanofi Recent Development
10.6 Bristol-Myers Squibb
10.6.1 Bristol-Myers Squibb Company Information
10.6.2 Bristol-Myers Squibb Introduction and Business Overview
10.6.3 Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Products Offered
10.6.5 Bristol-Myers Squibb Recent Development
10.7 Abbott Laboratories
10.7.1 Abbott Laboratories Company Information
10.7.2 Abbott Laboratories Introduction and Business Overview
10.7.3 Abbott Laboratories Antidiabetic Glucagon-like Peptide 1 Agonists Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Abbott Laboratories Antidiabetic Glucagon-like Peptide 1 Agonists Products Offered
10.7.5 Abbott Laboratories Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Antidiabetic Glucagon-like Peptide 1 Agonists Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Antidiabetic Glucagon-like Peptide 1 Agonists Industrial Chain Analysis
11.4 Antidiabetic Glucagon-like Peptide 1 Agonists Market Dynamics
11.4.1 Antidiabetic Glucagon-like Peptide 1 Agonists Industry Trends
11.4.2 Antidiabetic Glucagon-like Peptide 1 Agonists Market Drivers
11.4.3 Antidiabetic Glucagon-like Peptide 1 Agonists Market Challenges
11.4.4 Antidiabetic Glucagon-like Peptide 1 Agonists Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Antidiabetic Glucagon-like Peptide 1 Agonists Distributors
12.3 Antidiabetic Glucagon-like Peptide 1 Agonists Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Exenatied
Table 2. Major Company of Liraglutide
Table 3. Major Company of Lixisenatide
Table 4. Major Company of Albiglutide
Table 5. Major Company of Dulaglutide
Table 6. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Type 2018 VS 2022 VS 2029 (US$ Million)
Table 7. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Type (2018-2024) & (K Units)
Table 8. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Volume by Type (2018-2024)
Table 9. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Type (2018-2024) & (US& Million)
Table 10. Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Share in Value by Type (2018-2024)
Table 11. Global Antidiabetic Glucagon-like Peptide 1 Agonists Price by Type (2018-2024) & (US$/Unit)
Table 12. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Type (2024-2029) & (K Units)
Table 13. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Volume by Type (2024-2029)
Table 14. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Type (2024-2029) & (US$ Million)
Table 15. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Value by Type (2024-2029)
Table 16. Global Antidiabetic Glucagon-like Peptide 1 Agonists Price by Type (2024-2029) & (US$/Unit)
Table 17. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Type (2018-2024) & (K Units)
Table 18. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Type (2018-2024) & (US$ Million)
Table 19. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales (K Units) by Type (2018-2024)
Table 20. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Type (2018-2024) & (US$ Million)
Table 21. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales (K Units) by Type (2018-2024)
Table 22. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Type (2018-2024) & (US$ Million)
Table 23. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales (K Units) by Type (2018-2024)
Table 24. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Type (2018-2024) & (US$ Million)
Table 25. Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales (K Units) by Type (2018-2024)
Table 26. Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Type (2018-2024) & (US$ Million)
Table 27. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Company (2018-2024) & (K Units)
Table 28. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Share by Company (2018-2024)
Table 29. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Company (2018-2024) & (US$ Million)
Table 30. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue Share by Company (2018-2024)
Table 31. Global Market Antidiabetic Glucagon-like Peptide 1 Agonists Price by Company (2018-2024) & (US$/Unit)
Table 32. Global Antidiabetic Glucagon-like Peptide 1 Agonists Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 33. Global Antidiabetic Glucagon-like Peptide 1 Agonists Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 34. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Antidiabetic Glucagon-like Peptide 1 Agonists as of 2022)
Table 35. Date of Key Manufacturers Enter into Antidiabetic Glucagon-like Peptide 1 Agonists Market
Table 36. Key Manufacturers Antidiabetic Glucagon-like Peptide 1 Agonists Product Type
Table 37. Mergers & Acquisitions, Expansion Plans
Table 38. Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2029
Table 39. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Region (2018-2024) & (K Units)
Table 40. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Volume by Region (2018-2024)
Table 41. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Region (2018-2024) & (US$ Million)
Table 42. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Value by Region (2018-2024)
Table 43. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 44. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Region (2024-2029) & (K Units)
Table 45. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Volume by Region (2024-2029)
Table 46. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Region (2024-2029) & (US$ Million)
Table 47. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Value by Region (2024-2029)
Table 48. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2029)
Table 49. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application: 2018 VS 2022 VS 2029 (US$ Million)
Table 50. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application (2018-2024) & (K Units)
Table 51. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Volume by Application (2018-2024)
Table 52. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application (2018-2024) & (US$ Million)
Table 53. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Value by Application (2018-2024)
Table 54. Global Antidiabetic Glucagon-like Peptide 1 Agonists Price by Application (2018-2024) & (US$/Unit)
Table 55. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application (2024-2029) & (K Units)
Table 56. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Volume by Application (2024-2029)
Table 57. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application (2024-2029) & (US$ Million)
Table 58. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Value by Application (2024-2029)
Table 59. Global Antidiabetic Glucagon-like Peptide 1 Agonists Price by Application (2024-2029) & (US$/Unit)
Table 60. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application (2018-2024) (K Units)
Table 61. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application (2018-2024) & (US$ Million)
Table 62. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application (2018-2024) (K Units)
Table 63. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application (2018-2024) & (US$ Million)
Table 64. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application (2018-2024) (K Units)
Table 65. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application (2018-2024) & (US$ Million)
Table 66. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application (2018-2024) (K Units)
Table 67. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application (2018-2024) & (US$ Million)
Table 68. Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application (2018-2024) (K Units)
Table 69. Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application (2018-2024) & (US$ Million)
Table 70. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2018-2024) & (K Units)
Table 71. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Volume by Country (2018-2024)
Table 72. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2018-2024) & (US$ Million)
Table 73. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Value by Country (2018-2024)
Table 74. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2024-2029) & (K Units)
Table 75. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Volume by Country (2024-2029)
Table 76. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2024-2029) & (US$ Million)
Table 77. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Value by Country (2024-2029)
Table 78. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2018-2024) & (K Units)
Table 79. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Volume by Country (2018-2024)
Table 80. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2018-2024) & (US$ Million)
Table 81. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Value by Country (2018-2024)
Table 82. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2024-2029) & (K Units)
Table 83. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Volume by Country (2024-2029)
Table 84. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2024-2029) & (US$ Million)
Table 85. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Value by Country (2024-2029)
Table 86. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Region (2018-2024) & (K Units)
Table 87. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Volume by Region (2018-2024)
Table 88. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Region (2018-2024) & (US$ Million)
Table 89. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Value by Region (2018-2024)
Table 90. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Region (2024-2029) & (K Units)
Table 91. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Volume by Region (2024-2029)
Table 92. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Region (2024-2029) & (US$ Million)
Table 93. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Value by Region (2024-2029)
Table 94. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2018-2024) & (K Units)
Table 95. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Volume by Country (2018-2024)
Table 96. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2018-2024) & (US$ Million)
Table 97. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Value by Country (2018-2024)
Table 98. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2024-2029) & (K Units)
Table 99. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Volume by Country (2024-2029)
Table 100. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2024-2029) & (US$ Million)
Table 101. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Value by Country (2024-2029)
Table 102. Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2018-2024) & (K Units)
Table 103. Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Volume by Country (2018-2024)
Table 104. Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2018-2024) & (US$ Million)
Table 105. Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Value by Country (2018-2024)
Table 106. Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2024-2029) & (K Units)
Table 107. Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Volume by Country (2024-2029)
Table 108. Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Country (2024-2029) & (US$ Million)
Table 109. Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Value by Country (2024-2029)
Table 110. Novo Nordisk Company Information
Table 111. Novo Nordisk Introduction and Business Overview
Table 112. Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 113. Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Product
Table 114. Novo Nordisk Recent Development
Table 115. AstraZeneca Company Information
Table 116. AstraZeneca Introduction and Business Overview
Table 117. AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 118. AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Product
Table 119. AstraZeneca Recent Development
Table 120. Eli Lily Company Information
Table 121. Eli Lily Introduction and Business Overview
Table 122. Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 123. Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Product
Table 124. Eli Lily Recent Development
Table 125. GSK Company Information
Table 126. GSK Introduction and Business Overview
Table 127. GSK Antidiabetic Glucagon-like Peptide 1 Agonists Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 128. GSK Antidiabetic Glucagon-like Peptide 1 Agonists Product
Table 129. GSK Recent Development
Table 130. Sanofi Company Information
Table 131. Sanofi Introduction and Business Overview
Table 132. Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 133. Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Product
Table 134. Sanofi Recent Development
Table 135. Bristol-Myers Squibb Company Information
Table 136. Bristol-Myers Squibb Introduction and Business Overview
Table 137. Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 138. Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Product
Table 139. Bristol-Myers Squibb Recent Development
Table 140. Abbott Laboratories Company Information
Table 141. Abbott Laboratories Introduction and Business Overview
Table 142. Abbott Laboratories Antidiabetic Glucagon-like Peptide 1 Agonists Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 143. Abbott Laboratories Antidiabetic Glucagon-like Peptide 1 Agonists Product
Table 144. Abbott Laboratories Recent Development
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Antidiabetic Glucagon-like Peptide 1 Agonists Market Trends
Table 148. Antidiabetic Glucagon-like Peptide 1 Agonists Market Drivers
Table 149. Antidiabetic Glucagon-like Peptide 1 Agonists Market Challenges
Table 150. Antidiabetic Glucagon-like Peptide 1 Agonists Market Restraints
Table 151. Antidiabetic Glucagon-like Peptide 1 Agonists Distributors List
Table 152. Antidiabetic Glucagon-like Peptide 1 Agonists Downstream Customers
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Antidiabetic Glucagon-like Peptide 1 Agonists Product Picture
Figure 2. Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Size, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Size Status and Outlook (2018-2029) & (US$ Million)
Figure 4. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Status and Outlook (2018-2029) & (K Units)
Figure 5. Product Picture of Exenatied
Figure 6. Global Exenatied Sales YoY Growth (2018-2029) & (K Units)
Figure 7. Product Picture of Liraglutide
Figure 8. Global Liraglutide Sales YoY Growth (2018-2029) & (K Units)
Figure 9. Product Picture of Lixisenatide
Figure 10. Global Lixisenatide Sales YoY Growth (2018-2029) & (K Units)
Figure 11. Product Picture of Albiglutide
Figure 12. Global Albiglutide Sales YoY Growth (2018-2029) & (K Units)
Figure 13. Product Picture of Dulaglutide
Figure 14. Global Dulaglutide Sales YoY Growth (2018-2029) & (K Units)
Figure 15. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Type (2018-2029) & (US$ Million)
Figure 16. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Type in 2022 & 2029
Figure 17. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Volume by Type in 2022
Figure 18. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Value by Type in 2022
Figure 19. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Volume by Type in 2022
Figure 20. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Value by Type in 2022
Figure 21. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Volume by Type in 2022
Figure 22. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Value by Type in 2022
Figure 23. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Volume by Type in 2022
Figure 24. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Value by Type in 2022
Figure 25. Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Volume by Type in 2022
Figure 26. Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Value by Type in 2022
Figure 27. The 5 and 10 Largest Manufacturers in the World: Market Share by Antidiabetic Glucagon-like Peptide 1 Agonists Sales in 2022
Figure 28. The 5 and 10 Largest Manufacturers in the World: Market Share by Antidiabetic Glucagon-like Peptide 1 Agonists Revenue in 2022
Figure 29. Antidiabetic Glucagon-like Peptide 1 Agonists Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 30. Product Picture of Hospital
Figure 31. Global Hospital Sales YoY Growth (2018-2029) & (K Units)
Figure 32. Product Picture of Pharmacy
Figure 33. Global Pharmacy Sales YoY Growth (2018-2029) & (K Units)
Figure 34. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales by Application (2018-2029) & (US$ Million)
Figure 35. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share by Application in 2022 & 2029
Figure 36. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Volume by Application in 2022
Figure 37. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Value by Application in 2022
Figure 38. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Volume by Application in 2022
Figure 39. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Value by Application in 2022
Figure 40. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Volume by Application in 2022
Figure 41. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Value by Application in 2022
Figure 42. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Volume by Application in 2022
Figure 43. Latin America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Value by Application in 2022
Figure 44. Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Market Share in Value by Application in 2022
Figure 45. Key Raw Materials Price
Figure 46. Antidiabetic Glucagon-like Peptide 1 Agonists Manufacturing Cost Structure
Figure 47. Antidiabetic Glucagon-like Peptide 1 Agonists Industrial Chain Analysis
Figure 48. Channels of Distribution
Figure 49. Distributors Profiles
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries